Article

Forbes on 2017-10-06 17:57

Merck Hedges Bets With Keytruda Lung Study

Merck has started a big study testing whether its immunotherapy drug, Keytruda, helps newly diagnosed lung cancer patients more if it is combined with ...

Bristol

Related news

How Big Can Merck's Keytruda Be In Lung Cancer?Forbes
Bristol
MMerck stock rises 2.4% after new Keytruda lung cancer approval marketwatch.com
BMerck Stock Gains as FDA Accelerates Review of New Keytruda Indication barrons.com
China
MMerck leaps past rivals with latest lung cancer drug results marketwatch.com
Bristol , Europe , Wall Street
Revolut Hedges Its Bets On New Stock Trading Feature Forbes
Nirji , Australia , Europe
How Important Is Keytruda For Merck?Forbes
Kenilworth
Andy Richardson Column: Rishi Sunak lacks aim as he hedges his bets on a general election expressandstar.com
Bristol , Tamworth , Mid Bedfordshire District , Wellingborough , The Green
Merck beats expectations, helped by Keytruda sales dailyherald.com
New Jersey , Kenilworth , Wall Street
FDA Approves Merck’s Keytruda for Lung Cancer wsj.com
North America
Bristol-Myers drug fails lung cancer study, shares plunge dothaneagle.com
New Jersey , Bristol , New York , Lawrence
Germany’s Merck Overhauls Currency Hedges wsj.com
Argentina , Latin America , Turkey , Switzerland , Taiwan
MMerck stock slides as lung-cancer drug misses a study endpoint marketwatch.com
HMerck Scores a Hit With Keytruda, Watches Spending in 4Q hamodia.com
New Jersey , Wall Street
COVID-19 treatment, Keytruda boost Merck in 1Q Seattle Times
New Jersey , Kenilworth , China
Drugmaker Merck tops 3Q forecasts as Keytruda sales jump 20%Seattle Times
DMerck Posts Narrower Loss, Lifts Sales Forecast On Keytruda Boost dcourier.com